Budesonide orodispersible tablets maintain EoE remission
SAN DIEGO — Patients receiving budesonide orodispersible tablets for the treatment of eosinophilic esophagitis were able to maintain remission through 48 weeks, according to study...
Tag: Orodispersible
Efficacy of Budesonide Orodispersible Tablets as Induction Therapy for Eosinophilic Esophagitis in a Randomized Placebo-controlled Trial
Swallowed topical-acting corticosteroids are recommended as first-line therapy for eosinophilic esophagitis (EoE). Asthma medications not optimized for esophageal delivery are sometimes effective, although given off...